Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Gilead will provide Sovaldi® to the Egyptian ministry of health at a significantly reduced price, to be used as part of combination therapy. You can read more about this on the Gilead website viral hepatitis page and in their treatment expansion fact sheet.

NEWS & EVENT

Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more



fp7_01fp7_02 This project is funded
by the European Union